Transanal Tubes May Reduce Need for Further Surgery After Rectal Cancer Surgery but Leakage Prevention Uncertain
Using a soft transanal tube during rectal cancer surgery may reduce the need for subsequent corrective operations, according to evidence current to August 6, 2025. However, it remains uncertain whether these tubes effectively prevent the initial bowel connection leakage, and results vary significantly depending on whether a patient also receives a temporary diverting stoma.
Impact on Surgical Outcomes
Research summarized by Cochrane indicates that while transanal tubes are intended to decompress the rectum and improve drainage, their impact on preventing anastomotic leakage is not definitively proven. Across four studies involving 1,318 participants, the risk of leakage was 83 per 1,000 patients without a tube, compared to 73 per 1,000 patients with one.
Despite the uncertainty regarding initial leakage, the data suggests a potential reduction in the necessity for further surgical intervention. In groups using the tubes, the risk of requiring additional surgery was 14 per 1,000, compared to 45 per 1,000 for those who did not receive the device, according to Cochrane. One study of 398 patients also said that tube recipients were discharged from the hospital an average of 3.25 days earlier than others.
Diverting Stoma Considerations
The effectiveness of these tubes appears linked to other surgical choices. A meta-analysis published in the World Journal of Gastrointestinal Surgery noted that while overall results for symptomatic leakage remained controversial, patients who did not undergo a diverting stoma experienced a reduction in symptomatic leakage when a transanal drainage tube was used. Conversely, among patients who did receive a diverting stoma, leakage occurred more frequently when a transanal tube was also utilized, Cochrane reported.
The use of a diverting stoma remains a standard, albeit more invasive, method for protecting the bowel connection by redirecting the fecal stream.
According to research published via the National Center for Biotechnology Information, surgeons must weigh the potential benefits of stoma-sparing techniques like transanal tubes against the traditional approach, especially as reported incidence rates for leakage vary widely from 3.4% to 20% due to differences in patient risk factors and surgical expertise.
| Outcome Group | Risk without Tube (per 1,000) | Risk with Tube (per 1,000) |
|---|---|---|
| Anastomotic Leakage | 83 | 73 |
| Further Surgery Needed | 45 | 14 |
Patients may experience side effects from the procedure, with approximately 1 in 4 reporting pain or discomfort, and some instances where the tube was dislodged earlier than intended, Cochrane stated. Because the existing studies are generally small and varied in their surgical methods, researchers emphasize that more investigations are necessary to identify which specific patient populations derive the most benefit from transanal drainage tubes.
Cochrane is a global organization recognized for producing systematic reviews, which function as the gold standard for evidence-based health. By carefully examining all scientific research regarding a specific clinical question, the organization provides an objective and transparent overview of evidence. This process is considered authoritative because it employs sophisticated statistical methods to combine data from multiple clinical trials, creating more reliable results than individual studies alone.
Since its creation in 1993, Cochrane has maintained this rigorous approach to support informed decision-making for health professionals and systems worldwide. By utilizing standardized criteria to extract and judge research quality, the organization ensures that its evidence synthesis offers a more focused and confident conclusion than scattered, individual investigations.